Comments
Lupin has launched moxifloxacin ophthalmic solution USP, 0.5%, having received approval from the United States Food and Drug Administration earlier. The product would be manufactured at Lupin's Pithampur (Unit-II) facility, it said. The solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms. Moxifloxacin Ophthalmic Solution had an annual sales of approximately $10 million in the US (IQVIA MAT December 2019). Shares of drug maker Lupin closed 2 per cent higher at ₹717.85 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.